QSAR modeling: where have you been? Where are you going to?; The value of antimicrobial peptides in the age of resistance; Online chemical modeling environment (OCHEM): web platform for data storage, model development and publishing of chemical information; QSAR without borders; Rapid identification of potential inhibitors of SARS‐CoV‐2 main protease by deep docking of 1.3 billion compounds; Use of artificial intelligence in the design of small peptide antibiotics effective against a broad spectrum of highly antibiotic-resistant superbugs; Combinatorial QSAR modeling of chemical toxicants tested against Tetrahymena pyriformis; Identification of novel antibacterial peptides by chemoinformatics and machine learning; AMPer: a database and an automated discovery tool for antimicrobial peptides; SimBoost: a read-across approach for predicting drug–target binding affinities using gradient boosting machines; Applicability domains for classification problems: benchmarking of distance to models for Ames mutagenicity set; Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients; Deep docking: a deep learning platform for augmentation of structure based drug discovery; Targeting the binding function 3 (BF3) site of the human androgen receptor through virtual screening.; Evidence that plant-like genes in Chlamydia species reflect an ancestral relationship between Chlamydiaceae, cyanobacteria, and the chloroplast; Crystallographic structure of wild-type SARS-CoV-2 main protease acyl-enzyme intermediate with physiological C-terminal autoprocessing site; Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer; Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor; Therapeutic inhibition of Myc in cancer. Structural bases and computer-aided drug discovery approaches; A critical overview of computational approaches employed for COVID-19 drug discovery
